BioNTech (NASDAQ:BNTX) Shares Up 2.7%

BioNTech SE (NASDAQ:BNTX)’s share price rose 2.7% on Monday . The company traded as high as $88.93 and last traded at $88.85. Approximately 546,858 shares changed hands during mid-day trading, a decline of 17% from the average daily volume of 658,333 shares. The stock had previously closed at $86.48.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BNTX shares. BMO Capital Markets lowered their price target on BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research report on Thursday, March 21st. HC Wainwright dropped their target price on shares of BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research report on Tuesday, January 23rd. The Goldman Sachs Group reduced their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 28th. Oppenheimer assumed coverage on shares of BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating for the company. Finally, Canaccord Genuity Group restated a “buy” rating and set a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $120.40.

BioNTech Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The business’s fifty day simple moving average is $91.67 and its 200 day simple moving average is $97.64. The stock has a market cap of $20.57 billion, a price-to-earnings ratio of 20.77 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. Research analysts predict that BioNTech SE will post -1.67 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in BNTX. Captrust Financial Advisors raised its holdings in BioNTech by 6.9% in the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company’s stock valued at $159,000 after acquiring an additional 69 shares in the last quarter. Centaurus Financial Inc. raised its stake in shares of BioNTech by 5.2% in the 1st quarter. Centaurus Financial Inc. now owns 1,448 shares of the company’s stock valued at $247,000 after purchasing an additional 71 shares in the last quarter. Pathstone Family Office LLC lifted its position in shares of BioNTech by 4.9% during the fourth quarter. Pathstone Family Office LLC now owns 2,205 shares of the company’s stock worth $331,000 after purchasing an additional 103 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in BioNTech by 6.9% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock worth $186,000 after purchasing an additional 111 shares in the last quarter. Finally, Sectoral Asset Management Inc. grew its stake in BioNTech by 3.5% in the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock worth $374,000 after purchasing an additional 116 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.